22068 Federal Register / Vol. 60, No. 86 / Thursday, May 4, 1995 / Notices

ACTION: Notice of hearing.

SUMMARY: This notice announces an

administrative hearing on June 14, 1995,

at 10 a.m. in the 15th Floor Conference

Room, 105 West Adams, Chicago,

Illinois to reconsider our decision to

disapprove Illinois SPA 93–14.

CLOSING DATE: Requests to participate in

the hearing as a party must be received

by the presiding officer by May 19,

1995.

FOR FURTHER INFORMATION CONTACT: Stan

Katz, Presiding Officer, Ground floor,

Meadowwood East Building, 1849

Gwynn Oak Avenue, Baltimore,

Maryland 21207, Telephone: (410) 597–

3013.

SUPPLEMENTARY INFORMATION: This

notice announces an administrative

hearing to reconsider our decision to

disapprove Illinois State plan

amendment (SPA) number 93–14.

Section 1116 of the Social Security

Act (the Act) and 42 CFR part 430

establish Department procedures that

provide an administrative hearing for

reconsideration of a disapproval of a

State plan or plan amendment. The

Health Care Financing Administration

(HCFA) is required to publish a copy of

the notice to a State Medicaid agency

that informs the agency of the time and

place of the hearing and the issues to be

considered. If we subsequently notify

the agency of additional issues that will

be considered at the hearing, we will

also publish that notice.

Any individual or group that wants to

participate in the hearing as a party

must petition the presiding officer

within 15 days after publication of this

notice, in accordance with the

requirements contained at 42 CFR

430.76(b)(2). Any interested person or

organization that wants to participate as

amicus curiae must petition the

presiding officer before the hearing

begins in accordance with the

requirements contained at 42 CFR

430.76(c). If the hearing is later

rescheduled, the presiding officer will

notify all participants.

The State of Illinois submitted SPA

93–14 on October 18, 1994, to establish

a new payment adjustment for

uncompensated care services, and

requested an effective date of July 1,

1993.

The issue in this matter is whether

Illinois SPA 93–14, meets Federal

regulations which require the State to

comply with the public notice

requirements in Section 447.205.

Illinois published public notice on

August 6, 1993, with the plan

amendment’s proposed effective date of

July 1, 1993.

HCFA believes the proposed effective

date of the plan amendment was not

approvable because the State failed to

comply with the Federal regulation at

42 CFR 447.253(h) which requires that

the Medicaid agency must comply with

public notice requirements in § 447.205

when it is proposing significant changes

to its methods and standards for setting

payment rates for inpatient hospital and

long-term care facility services. Section

447.225(d)(1) requires that the notice be

published before the proposed effective

date of the change. The State’s requested

effective date is prior to the date of the

public notice announcement.

However, because public notice was

published on August 5, 1993, HCFA

believes the plan amendment was

approvable with an effective date of

August 6, 1993.

The State of Illinois contends that the

change was not significant.

Additionally, Illinois challenges HCFA’s

disapproval because public notice was

published prior to the State’s

implementation of the amendment, and

because the eventual disallowances of

Federal financial participation funds

based on public notice requirements are

the subject of current regulatory reform

proposals.

Under HCFA’s policy, the sole factor

in determining a significant change is

the degree to which the State is

proposing to modify its payment

methods and standards. HCFA believes

since this amendment established a new

payment adjustment for uncompensated

care services, the amendment represents

a significant change in the methods and

standards used to determine payment

rates.

The notice to Illinois announcing an

administrative hearing to reconsider the

disapproval of its SPA reads as follows:

Mr. Robert W. Wright,

Director, Illinois Department of Public Aid,

Jesse B. Harris Building II, 3rd Floor, 100

South Grand Avenue, East, Springfield,

Illinois 62762–0001

Dear Mr. Wright: I am responding to your

request for reconsideration of the decision to

disapprove Illinois State Plan Amendment

(SPA) 93–14. The State of Illinois submitted

SPA 93–14 on October 18, 1994, to establish

a new payment adjustment for

uncompensated care services, and requested

an effective date of July 1, 1993.

The issue in this matter is whether Illinois

SPA 93–14, meets Federal regulations at 42

CFR 447.253(h) which require the State to

comply with the public notice requirements

in section 447.205.

I am scheduling a hearing on your request

for reconsideration to be held on June 14,

1995, at 10 a.m. in the 15th floor conference

room, 105 West Adams, Chicago, Illinois. If

this date is not acceptable, we would be glad

to set another date that is mutually agreeable

to the parties. The hearing will be governed

by the procedures prescribed at 42 CFR, Part

430.

I am designating Mr. Stanley Katz as the

presiding officer. If these arrangements

present any problems, please contact the

presiding officer. In order to facilitate any

communication which may be necessary

between the parties to the hearing, please

notify the presiding officer to indicate

acceptability of the hearing date that has

been scheduled and provide the names of the

individuals who will represent the State at

the hearing. The presiding officer may be

reached at (410) 597–3013.

Sincerely,

Bruce C. Vladeck,

Administrator.

(Sec. 1116 of the Social Security Act (42

U.S.C. section 1316); 42 CFR 430.18)

(Catalog of Federal Domestic Assistance

Program No. 13.714, Medicaid Assistance

Program)

Dated: April 28, 1995.

Bruce C. Vladeck,

Administrator, Health Care Financing

Administration.

[FR Doc. 95–11019 Filed 5–3–95; 8:45 am]

BILLING CODE 4120–01–P

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS,

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and
Federal Register / Vol. 60, No. 86 / Thursday, May 4, 1995 / Notices 22069

will be omitted from the monthly listing

thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh, Division of Workplace

Programs, Room 13A–54, 5600 Fishers

Lane, Rockville, Maryland 20857; Tel.:

(301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACCU-LAB, Inc., 405 Alderson St.,

Schofield, WI 54476, 800–627–8200

(formerly: Alpha Medical Laboratory,

Inc., Employee Health Assurance

Group, ExpressLab, Inc.)

Aegis Analytical Laboratories, Inc., 624

Grassmere Park Rd., Suite 21,

Nashville, TN 37211, 615–331–5300

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/205–263–5745

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

22021, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–227–2783

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Bayshore Clinical Laboratory, 4555 W.

Schroeder Dr., Brown Deer, WI 53223,

414–355–4444/800–877–7016

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5810

Centinela Hospital Airport Toxicology

Laboratory, 9601 S. Sepulveda Blvd.,

Los Angeles, CA 90045, 310–215–

6020

Clinical Reference Lab, 11850 West 85th

St., Lenexa, KS 66214, 800–445–6917

CORNING Clinical Laboratories, South

Central Divison, 2320 Schuetz Rd., St.

Louis, MO 63146, 800–288–7293

(formerly: Metropolitan Reference

Laboratories, Inc.)

CORNING Clinical Laboratories, 8300

Esters Blvd., Suite 900, Irving, TX

75063, 800–526–0947 (formerly:

Damon Clinical Laboratories, Damon/

MetPath)

CORNING MetPath Clinical

Laboratories, 1355 Mittel Blvd., Wood

Dale, IL 60191, 708–595–3888

(formerly: MetPath, Inc.)

CORNING MetPath Clinical

Laboratories, One Malcolm Ave.,

Teterboro, NJ 07608, 201–393–5000

(formerly: MetPath, Inc.)

CORNING National Center for Forensic

Science, 1901 Sulphur Spring Rd.,

Baltimore, MD 21227, 410–536–1485

(formerly: Maryland Medical

Laboratory, Inc., National Center for

Forensic Science)

CORNING Nichols Institute, 7470–A

Mission Valley Rd., San Diego, CA

92108–4406, 800–446–4728/619–686–

3200 (formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT))

Cox Medical Centers, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–836–3093

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building

38–H, Great Lakes, IL 60088–5223,

708–688–2045/708–688–4171

Diagnostic Services Inc., dba DSI, 4048

Evans Ave., Suite 301, Fort Myers, FL

33901, 813–936–5446/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31604,

912–244–4468

Drug Labs of Texas, 15201 I–10 East,

Suite 125, Channelview, TX 77530,

713–457–3784

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

800–898–0180 / 206–386–2672

(formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

Eagle Forensic Laboratory, Inc., 950 N.

Federal Highway, Suite 308, Pompano

Beach, FL 33062, 305–946–4324

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 601–236–

2609

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–

267–6267

Harrison Laboratories, Inc., 9930 W.

Highway 80, Midland, TX 79706,

800–725–3784/915–563–3300

(formerly: Harrison & Associates

Forensic Laboratories)

HealthCare/MetPath, 24451 Telegraph

Rd., Southfield, MI 48034, 800–444–

0106 ext. 650 (formerly: HealthCare/

Preferred Laboratories)

Holmes Regional Medical Center

Toxicology Laboratory, 5200 Babcock

St., N.E., Suite 107, Palm Bay, FL

32905, 407–726–9920

Jewish Hospital of Cincinnati, Inc., 3200

Burnet Ave., Cincinnati, OH 45229,

513–569–2051

LabOne, Inc., 8915 Lenexa Dr., Overland

Park, Kansas 66214, 913–888–3927

(formerly: Center for Laboratory

Services, a Division of LabOne, Inc.)

Laboratory Specialists, Inc., 113 Jarrell

Dr., Belle Chasse, LA 70037, 504–

392–7961

Marshfield Laboratories, 1000 North

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–222–5835

MedExpress/National Laboratory

Center, 4022 Willow Lake Blvd.,

Memphis, TN 38175, 901–795–1515

Medical College Hospitals Toxicology

Laboratory, Department of Pathology,

3000 Arlington Ave., Toledo, OH

43699–0008, 419–381–5213

Medlab Clinical Testing, Inc., 212

Cherry Lane, New Castle, DE 19720,

302–655–5227

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

800–832–3244/612–636–7466

Methodist Hospital of Indiana, Inc.,

Department of Pathology and

Laboratory Medicine, 1701 N. Senate

Blvd., Indianapolis, IN 46202, 317–

929–3587

Methodist Medical Center Toxicology

Laboratory, 221 N.E. Glen Oak Ave.,

Peoria, IL 61636, 800–752–1835/309–

671–5199

MetPath Laboratories, 875 Greentree

Rd., 4 Parkway Ctr., Pittsburgh, PA

15220–3610, 412–931–7200 (formerly:

Med-Chek Laboratories, Inc., MedChek/Damon)

MetroLab-Legacy Laboratory Services,

235 N. Graham St., Portland, OR

97227, 503–413–4512, 800–237–7808

(x4512)

National Health Laboratories

Incorporated, 2540 Empire Dr.,

Winston-Salem, NC 27103–6710,
22070 Federal Register / Vol. 60, No. 86 / Thursday, May 4, 1995 / Notices

Outside NC: 919–760–4620/800–334–

8627 / Inside NC: 800–642–0894

National Health Laboratories

Incorporated, d.b.a. National

Reference Laboratory, Substance

Abuse Division, 1400 Donelson Pike,

Suite A–15, Nashville, TN 37217,

615–360–3992/800–800–4522

National Health Laboratories

Incorporated, 13900 Park Center Rd.,

Herndon, VA 22071, 703–742–3100

National Psychopharmacology

Laboratory, Inc., 9320 Park W. Blvd.,

Knoxville, TN 37923, 800–251–9492

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield, CA

93304, 805–322–4250

Northwest Toxicology, Inc., 1141 E.

3900 South, Salt Lake City, UT 84124,

800–322–3361

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 503–687–2134

Pathology Associates Medical

Laboratories, East 11604 Indiana,

Spokane, WA 99206, 509–926–2400

PDLA, Inc. (Princeton), 100 Corporate

Court, So. Plainfield, NJ 07080, 908–

769–8500/800–237–7352

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025,

415–328–6200/800–446–5177

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort Worth,

TX 76118, 817–595–0294 (formerly:

Harris Medical Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–338–4070/800–821–3627

(formerly: Physicians Reference

Laboratory Toxicology Laboratory)

Poisonlab, Inc., 7272 Clairemont Mesa

Rd., San Diego, CA 92111, 619–279–

2600/800–882–7272

Puckett Laboratory, 4200 Mamie St.,

Hattiesburgh, MS 39402, 601–264–

3856/800–844–8378

Regional Toxicology Services, 15305

N.E. 40th St., Redmond, WA 98052,

206–882–3400

Roche Biomedical Laboratories, Inc.,

1120 Stateline Rd., Southaven, MS

38671, 601–342–1286

Roche Biomedical Laboratories, Inc., 69

First Ave., Raritan, NJ 08869, 800–

437–4986

Roche CompuChem Laboratories, Inc., A

Member of the Roche Group, 3308

Chapel Hill/Nelson Hwy., Research

Triangle Park, NC 27709, 919–549–

8263/800–833–3984 (Formerly:

CompuChem Laboratories, Inc., A

Subsidiary of Roche Biomedical

Laboratory)

Roche CompuChem Laboratories, Inc.,

Special Division, A Member of the

Roche Group, 3308 Chapel Hill/

Nelson Hwy., Research Triangle Park,

NC 27709, 919–549–8263 (Formerly:

CompuChem Laboratories, Inc.—

Special Division)

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

Scott & White Drug Testing Laboratory,

600 S. 25th St., Temple, TX 76504,

800–749–3788

S.E.D. Medical Laboratories, 500 Walter

NE, Suite 500, Albuquerque, NM

87102, 505–848–8800

Sierra Nevada Laboratories, Inc. 888

Willow St. Reno, NV 89502 800–648–

5472

SmithKline Beecham Clinical

Laboratories, 7600 Tyrone Ave., Van

Nuys, CA 91045, 818–376–2520

SmithKline Beecham Clinical

Laboratories, 801 East Dixie Ave.,

Leesburg, FL 34748, 904–787–9006

(formerly: Doctors & Physicians

Laboratory)

SmithKline Beecham Clinical

Laboratories, 3175 Presidential Dr.,

Atlanta, GA 30340, 404–934–9205

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 506 E. State Pkwy.,

Schaumburg, IL 60173, 708–885–2010

(formerly: International Toxicology

Laboratories)

SmithKline Beecham Clinical

Laboratories, 400 Egypt Rd.,

Norristown, PA 19403, 800–523–5447

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 8000 Sovereign Row,

Dallas, TX 75247, 214–638–1301

(formerly: SmithKline Bio-Science

Laboratories)

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Southwest Laboratories, 2727 W.

Baseline Rd., Suite 6, Tempe, AZ

85283, 602–438–8507

St. Anthony Hospital (Toxicology

Laboratory), P.O. Box 205, 1000 N.

Lee St., Oklahoma City, OK 73102,

405–272–7052

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 301 Business Loop

70 West, Suite 208, Columbia, MO

65203, 314–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

TOXWORX Laboratories, Inc., 6160

Variel Ave., Woodland Hills, CA

91367, 818–226–4373 (formerly:

Laboratory Specialists, Inc.; Abused

Drug Laboratories; MedTox BioAnalytical, a Division of MedTox

Laboratories, Inc.)

UNILAB, 18408 Oxnard St., Tarzana,

CA 91356, 800–492–0800/818–343–

8191 (formerly: MetWest-BPL

Toxicology Laboratory)

No laboratories withdrew from the

Program in April.

Richard Kopanda,

Acting Executive Officer, Substance Abuse

and Mental Health Services Administration.

[FR Doc. 95–11044 Filed 5–3–95; 8:45 am]

BILLING CODE 4160–20–U

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[CA–020–5101–10-B038; CACA–31406,

NVN–57250]

Alturas 345 Kilovolt Transmission Line

Project; California

AGENCY: Bureau of Land Management,

Interior; Susanville District Office,

California.

ACTION: Amendment to Notice of

Availability of a Draft Environmental

Impact Statement (EIS No. 950068).

SUMMARY: The Bureau of Land

Management (BLM) and the California

Public Utilities Commission (CPUC)

have prepared a draft Environmental

Impact Report/Statement (EIR/S) for the

Alturas 345 kilovolt (KV) transmission

line project proposed by Sierra Pacific

Power Company (SPPCo) in BLM

application number CACA–31406. The

BLM notice of availability of the draft

EIR/S was published in the Federal

Register on March 9, 1995 (60 FR

12967–12968), and provided a comment

period on the draft EIR/S that ended

May 3, 1995. This Amendment to the

BLM notice of availability of a Draft

EIR/S hereby extends the comment

period until June 2, 1995. All comments

on the Draft EIR/S for the Alturas 345

kilovolt (KV) transmission line project

must be postmarked no later than June

2, 1995, and must be sent to: Julie

Halligan/Peter Humm, CPUC/BLM; c/o

Aspen Environmental Group; 30423

Canwood Street, Suite 218, Agoura

Hills, CA 91301. For information call

Peter Humm, BLM Project Manager, at

(916) 257–0456.

Dated: April 27, 1995.

John Bosworth,

Acting District Manager.

[FR Doc. 95–11000 Filed 5–3–95; 8:45 am]

BILLING CODE 4310–40–M